Y Intercept Hong Kong Ltd Reduces Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Y Intercept Hong Kong Ltd lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,720 shares of the biopharmaceutical company's stock after selling 796 shares during the period. Y Intercept Hong Kong Ltd's holdings in Alnylam Pharmaceuticals were worth $1,004,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Investment Management Corp of Ontario grew its stake in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after buying an additional 40 shares during the last quarter. Brevan Howard Capital Management LP grew its stake in shares of Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after buying an additional 44 shares during the last quarter. Lindbrook Capital LLC grew its stake in shares of Alnylam Pharmaceuticals by 9.2% in the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 50 shares during the last quarter. Ballentine Partners LLC grew its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 1st quarter. Ballentine Partners LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $439,000 after buying an additional 52 shares during the last quarter. Finally, National Bank of Canada FI grew its stake in shares of Alnylam Pharmaceuticals by 9.0% in the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock worth $157,000 after buying an additional 55 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research note on Monday, June 30th. BMO Capital Markets increased their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. Jefferies Financial Group increased their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Finally, JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $347.75.

Alnylam Pharmaceuticals Trading Up 0.2%

NASDAQ ALNY traded up $0.81 during trading hours on Friday, hitting $328.81. 666,674 shares of the company were exchanged, compared to its average volume of 911,887. The stock has a 50-day moving average price of $310.69 and a 200 day moving average price of $274.03. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $333.70. The stock has a market cap of $42.87 billion, a PE ratio of -157.33 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period in the previous year, the firm earned ($0.16) earnings per share. The company's revenue was up 20.2% compared to the same quarter last year. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.